Jason Halladay

2.3k total citations
42 papers, 769 citations indexed

About

Jason Halladay is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Jason Halladay has authored 42 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 17 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Jason Halladay's work include Pharmacogenetics and Drug Metabolism (22 papers), Drug Transport and Resistance Mechanisms (12 papers) and Computational Drug Discovery Methods (7 papers). Jason Halladay is often cited by papers focused on Pharmacogenetics and Drug Metabolism (22 papers), Drug Transport and Resistance Mechanisms (12 papers) and Computational Drug Discovery Methods (7 papers). Jason Halladay collaborates with scholars based in United States, France and Austria. Jason Halladay's co-authors include S. Cyrus Khojasteh, Jane R. Kenny, Cornelis E. C. A. Hop, Susan Wong, Saileta Prabhu, Anthony Y.H. Lu, Jasleen K. Sodhi, Sami Haddad, Patrick Poulin and Leonid M. Berezhkovskiy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jason Halladay

41 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Halladay United States	16	344	328	255	112	60	42	769
Rowan Stringer Switzerland	17	267 0.8×	232 0.7×	216 0.8×	99 0.9×	59 1.0×	23	874
Jairam Palamanda United States	19	339 1.0×	252 0.8×	223 0.9×	94 0.8×	64 1.1×	35	968
David B. Duignan United States	17	478 1.4×	278 0.8×	514 2.0×	103 0.9×	57 0.9×	25	1.1k
Stephen Fowler Switzerland	22	560 1.6×	321 1.0×	314 1.2×	149 1.3×	73 1.2×	47	1.1k
Ken Grime United Kingdom	18	557 1.6×	271 0.8×	404 1.6×	188 1.7×	96 1.6×	36	1.1k
Jackie C. Bloomer United Kingdom	13	268 0.8×	261 0.8×	180 0.7×	54 0.5×	58 1.0×	20	751
Yukiko Nakajima Japan	14	332 1.0×	225 0.7×	266 1.0×	64 0.6×	55 0.9×	33	790
Upendra A. Argikar United States	19	478 1.4×	406 1.2×	310 1.2×	117 1.0×	110 1.8×	55	1.2k
Lili Chen China	15	145 0.4×	365 1.1×	162 0.6×	145 1.3×	67 1.1×	35	862
Hugues Dolgos Germany	16	392 1.1×	208 0.6×	227 0.9×	186 1.7×	80 1.3×	26	792

Countries citing papers authored by Jason Halladay

Since Specialization

Citations

This map shows the geographic impact of Jason Halladay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Halladay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Halladay more than expected).

Fields of papers citing papers by Jason Halladay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Halladay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Halladay. The network helps show where Jason Halladay may publish in the future.

Co-authorship network of co-authors of Jason Halladay

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Halladay. A scholar is included among the top collaborators of Jason Halladay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Halladay. Jason Halladay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matusow, Bernice, Wayne Spevak, Yan Ma, et al.. (2024). Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC. Cancer Research. 84(6_Supplement). 660–660.

Mařı́k, Jan, Gauri Deshmukh, Donglu Zhang, et al.. (2023). GTP1 metabolic stability assessment: A study of the tau PET tracer [18F]GTP1. Nuclear Medicine and Biology. 124-125. 108386–108386. 1 indexed citations

Padilla, Ángel M., Wei Wang, Tsutomu Akama, et al.. (2022). Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates. Nature Microbiology. 7(10). 1536–1546. 39 indexed citations

Sodhi, Jasleen K. & Jason Halladay. (2021). Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). Methods in molecular biology. 2342. 765–779. 2 indexed citations

Takahashi, Ryan, Jason Halladay, Michael Siu, et al.. (2017). Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450. Drug Metabolism and Disposition. 45(5). 430–440. 11 indexed citations

Fan, Peter W., Dawei Zhang, Jason Halladay, James P. Driscoll, & S. Cyrus Khojasteh. (2016). Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase. Drug Metabolism and Disposition. 44(8). 1253–1261. 19 indexed citations

Ford, Kevin A., et al.. (2015). Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metabolism Reviews. 47(3). 291–319. 15 indexed citations

Blackwood, Elizabeth, Jennifer Epler, Ivana Yen, et al.. (2013). Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900. Molecular Cancer Therapeutics. 12(10). 1968–1980. 22 indexed citations

Poulin, Patrick, Donna M. Dambach, Kevin A. Ford, et al.. (2013). An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters. Journal of Pharmaceutical Sciences. 102(10). 3816–3829. 9 indexed citations

10.

Markova, Svetlana, Teresa De Marco, Joel Mefford, et al.. (2013). Association of CYP2C9*2 With Bosentan-Induced Liver Injury. Clinical Pharmacology & Therapeutics. 94(6). 678–686. 36 indexed citations

11.

Poulin, Patrick, et al.. (2012). Comparative Assessment of In Vitro–In Vivo Extrapolation Methods used for Predicting Hepatic Metabolic Clearance of Drugs. Journal of Pharmaceutical Sciences. 101(11). 4308–4326. 57 indexed citations

12.

Halladay, Jason, Susan Wong, S. Cyrus Khojasteh, & Susan Grepper. (2012). An ‘all-inclusive’ 96-well cytochrome P450 induction method: Measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. Journal of Pharmacological and Toxicological Methods. 66(3). 270–275. 27 indexed citations

13.

Khojasteh, S. Cyrus, Saileta Prabhu, Jane R. Kenny, Jason Halladay, & Anthony Y.H. Lu. (2011). Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. European Journal of Drug Metabolism and Pharmacokinetics. 36(1). 1–16. 116 indexed citations

14.

Salphati, Laurent, Jodie Pang, Emile G. Plise, et al.. (2011). Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica. 41(12). 1088–1099. 20 indexed citations

15.

Berezhkovskiy, Leonid M., Ning Liu, & Jason Halladay. (2011). Consistency of the Novel Equations for Determination of Hepatic Clearance and Drug Time Course in Liver that Account for the Difference in Drug Ionization in Extracellular and Intracellular Tissue Water. Journal of Pharmaceutical Sciences. 101(2). 516–518. 10 indexed citations

16.

Halladay, Jason, et al.. (2011). High-Throughput, 384-Well, LC-MS/MS CYP Inhibition Assay Using Automation, Cassette-Analysis Technique and Streamlined Data Analysis. Drug Metabolism Letters. 5(3). 220–230. 14 indexed citations

17.

Wong, Harvey, Jason Halladay, Jane R. Kenny, et al.. (2009). Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica. 39(11). 850–861. 47 indexed citations

18.

Berezhkovskiy, Leonid M., S. Cyrus Khojasteh, Jason Halladay, & Cornelis E. C. A. Hop. (2008). On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. Journal of Pharmaceutical Sciences. 98(6). 1922–1927. 18 indexed citations

19.

Halladay, Jason, et al.. (2007). Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching. Drug Metabolism Letters. 1(1). 67–72. 20 indexed citations

20.

Halladay, Jason, Carl R. Mackerer, Lorraine E. Twerdok, & I.G. Sipes. (2002). Comparative Pharmacokinetic and Disposition Studies of [1-14C]1-Eicosanylcyclohexane, a Surrogate Mineral Hydrocarbon, in Female Fischer-344 and Sprague-Dawley Rats. Drug Metabolism and Disposition. 30(12). 1470–1477. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact